A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Ku, Hsun Teresa, Ph.D. Research Bookmark and Share

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 

Ku, Hsun Teresa, Ph.D. Research

Hsun Teresa Ku, Ph.D. Research

Identification and Characterization of Pancreatic Stem Cells
A functional pancreas consists of two types of tissue: exocrine and endocrine. The exocrine tissue mainly consists of acinar cells, which secrete bicarbonate and digestive enzymes. These secretions are collected by the pancreatic ductal system, which begins with centroacinar cells that are directly in contact with acinar cells. The prolongation of the terminal ducts, or alveoli, are lined by centroacinar cells and gradually merge into a main duct that drains into the duodenum. The endocrine tissue is organized as islets and contains cells that secrete glucagon, insulin, somatostatin, pancreatic polypeptide or grehlin. These endocrine hormones are released directly into the blood stream in response to metabolic signals.
 
Recently, there has been an intense interest in identifying pancreatic stem or progenitor cells, especially the endocrine progenitor cells, for the purpose of replacement therapy of Type 1 diabetes (T1D), a disease in which the insulin-secreting beta cells are specifically destroyed by autoimmunity. However, the existence of self-renewing multipotential stem cells in the pancreas remains elusive. Our laboratory is interested in the identification and characterization of pancreatic stem/progenitor cells, using both mouse models and cadaverous human pancreatic tissues for studies. We have established a quantitative and clonogenic progenitor cell assay in our laboratory, which will be a powerful tool to study the cellular and molecular mechanisms that govern the differentiation and proliferation of the pancreatic stem/progenitor cells at the single cell level.
 
Embryonic Stem Cell Therapy for Type 1 Diabetes
T1D is marked by a deficiency of the insulin-secreting β cells residing in the Islets of Langerhans within the pancreas due to autoimmune destruction. One of the long-term goals of our laboratory is to advance clinical cell-replacement therapy for patients with sever forms of T1D by developing a safe, reliable and abundant source of cells, derived from human stem cells that function like pancreatic islets. Toward this end, we have established an efficient and potentially cost-effective differentiation protocol, originally adapted from a mouse embryonic stem cell (ESC) differentiation method previously established in our laboratory, and generated a population of glucose-responsive, insulin-producing and secreting cells derived from human ESCs while in vitro. This cell population will be a suitable development candidate for clinical cell replacement therapy for T1D at City of Hope in the future.
 
Embryonic Stem Cells as a Cellular Tool for Screening of Molecules for Treatment of Diabetes
In the small molecule drug discovery field, the “bottom-up” approach, which is based on structural considerations of known targets, has not been as fruitful as was once promised. ESC technology ffers a potential solution to this bottleneck. ESCs can be grown in large numbers and maintained in a pluripotent state in vitro. They can also be induced in culture to differentiate into cells from all three germ layers in a relatively normal fashion that is faithful to development in vivo. Three properties make ES cells an ideal platform for drug discovery: first, ES cells can provide virtually inexhaustible quantities of target cells, which is necessary for screening of large numbers of compounds; second, ES cells can differentiate into mature cells with phenotypes that mimic their counterparts in vivo; and third, compared with immortalized cell lines, ES cells and their derivatives will provide a much more accurate platform for the “top-down” drug screening approach. Our laboratory is interested in high throughput screening (HTS) of small molecules that may affect proliferation, differentiation and/or maturation of the pancreatic insulin-producing  β cells and their immediate progenitors. We have established a relatively simple and inexpensive differentiation protocol that allows efficient generation of the pancreatic like, insulin-expressing cells from murine ESCs. Thus, this ESC to pancreatic lineage differentiation assay will be valuable to serve as a cellular tool for screening large number of molecules that could be used to treat diabetes.
 
 
 

Lab Members

H. Teresa Ku, Ph.D. Lab Members

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H. Teresa Ku, Ph.D.
Professor
626-256-HOPE (4673), ext. 61174
 
Jeanne LeBon, Ph.D.
Assistant Research Professor
626-256-HOPE (4673), ext. 63796
 
Dan Gao, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 62251
 
Liang Jin, Ph.D.
Postdoctoral Fellow
626-256-HOPE (4673), ext. 61449
 
Lena Wedeken, Ph.D.,
Postdoctoral Fellow and a CIRM Postdoctoral Scholar
626-256-HOPE (4673), ext. 33242
 
Stephanie Walker, B.S.
Research Associate I
626-256-HOPE (4673), ext. 31235
 
Nadiah Ghazalli, M.S.
Graduate Student and a CIRM Predoctoral Scholar
626-256-HOPE (4673), ext. 31235
 
Center for Biomedicine & Genetics
Our Center for Biomedicine & Genetics (CBG) manufactures promising new genetic and cellular agents created by researches for use inclinical trials. We are uniquely equipped to evaluate therapies swiftly and move lifesaving drugs into the marketplace with great speed.
City of Hope has been the home of many illustrious scientists, including six members of the prestigious National Academy of Sciences: Ernest Beutler, Alfred Knudson, Rachmiel Levine, Susumo Ohno, Eugene Roberts, and Arthur Riggs. Learn more about our current scientists and researchers.
Cytogenetics Office Location
City of Hope and Beckman Research Institute 1500 East Duarte Road Duarte, CA 91010-3000 Northwest Building
Room 2265

Phone: 626-256-HOPE (4673), ext. 62025
Fax: 626-301-8877

Biostatistics Office Location
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000

Information Sciences Building (#171)

Phone:  626-256-HOPE (4673), Ext. 61444
Fax:  626-471-7106
or 626-301-8802
 
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 


NEWS & UPDATES
  • Surgery is vital in the treatment of cancer – it’s used to help diagnose, treat and even prevent the disease – so a new colorectal cancer study linking a decrease in surgeries for advanced cancer to increased survival rates may raise more questions than it answers for some patients. The surgery-and-surviv...
  • Age is the single greatest risk factor overall for cancer; our chances of developing the disease rise steeply after age 50. For geriatric oncology nurse Peggy Burhenn, the meaning is clear: Cancer is primarily a geriatric condition. That’s why she is forging inroads in the care of older adults with cancer. Burh...
  • One of American’s great sportscasters, Stuart Scott, passed away from recurrent cancer of the appendix at the young age of 49. His cancer was diagnosed when he was only 40 years old. It was found during an operation for appendicitis. His courageous fight against this disease began in 2007, resumed again with an...
  • When Homa Sadat found a lump in her breast at age 27, her gynecologist told her what many doctors say to young women: You’re too young to have breast cancer. With the lump dismissed as a harmless cyst, she didn’t think about it again until she was at a restaurant six months later and felt […]
  • What most people call a “bone marrow transplant” is not actually a transplant of bone marrow; it is instead the transplantation of what’s known as hematopoietic stem cells. Such cells are often taken from bone marrow, but not always. Hematopoietic stem cells are simply immature cells that can ...
  • Doctors have long known that women with a precancerous condition called atypical hyperplasia have an elevated risk of breast cancer. Now a new study has found that the risk is more serious than previously thought. Hyperplasia itself is an overgrowth of cells; atypical hyperplasia is an overgrowth in a distorted...
  • Don’t kid yourself. Just because it’s mid-January doesn’t mean it’s too late to make resolutions for a happier, and healthier, 2015. Just consider them resolutions that are more mature than those giddy, sometimes self-deluded, Jan. 1 resolutions. To that end, we share some advice from Cary A. Presant, M.D., an ...
  • Sales and marketing executive Jim Murphy first came to City of Hope in 2002 to donate blood for a friend who was being treated for esophageal cancer. The disease is serious. Although esophageal cancer accounts for only about 1 percent of cancer diagnoses in the U.S., only about 20 percent of patients survive at...
  • Aaron Bomar and his family were celebrating his daughter’s 33rd birthday in September 2014 when he received alarming news: According to an X-ray taken earlier that day at an urgent care facility, he had a node on his aorta and was in danger of an aneurysm. Bomar held hands with his wife and daughter and s...
  • Explaining a prostate cancer diagnosis to a young child can be difficult — especially when the cancer is incurable. But conveying the need for prostate cancer research, as it turns out, is easily done. And that leads to action. Earlier this year, Gerald Rustad, 71, who is living with a very aggressive form of m...
  • Cancer and its treatment can create unexpected daily challenges for patients. Side effects from chemotherapy, surgery and radiation therapy as well as the disease itself can cause difficulty in everything from speech to movement to eating. When this happens, rehabilitation is vital; it helps patients restore th...
  • Betsy Sauer and her four daughters share plenty in common. They’re smart and successful.  They’re funny, ranging from wryly witty to wickedly hilarious. Their hobbies tend toward the active and adventurous: hiking, rock climbing, skiing, swimming, fishing, kayaking, yoga and horseback riding. Also, they take he...
  • Flu season is upon us, and few people should take the risk of infection more seriously than cancer patients and their loved ones and caregivers. With the federal Centers for Disease Control and Prevention warning of widespread influenza outbreaks, it’s clear that flu season – and the associated risks – won’t en...
  • HIV/AIDS researchers are determined not only to cure the disease, but to develop ever-more-effective treatments until that ultimate goal is reached. In 2015, they will gain ground in both endeavors. In search of a cure: Stem cell and gene therapy One of the most promising prospects for curing HIV is to recreate...
  • Every year, researchers make gains in the understanding of cancer, and physicians make gains in the treatment of cancer. As a result, every year, more cancer patients survive their disease. In those ways, 2015 will be no different. What will be different are the specific research discoveries and the specific ad...